Abstract
We designed new 3-arylthio- and 3-aroyl-1H-indole derivatives 3–22 bearing a heterocyclic ring at position 5, 6 or 7 of the indole nucleus. The 6- and 7-heterocyclyl-1H-indoles showed potent inhibition of tubulin polymerization, binding of colchicine to tubulin and growth of MCF-7 cancer cells. Compounds 13 and 19 inhibited a panel of cancer cells and the NCI/ADR-RES multidrug resistant cell line at low nanomolar concentrations. Compound 13 at 50 nM induced 77% G2/M in HeLa cells, and at 20 nM caused 50% stable arrest of mitosis. As an inhibitor of HepG2 cells (IC50 = 20 nM), 13 was 4-fold superior to 19. Compound 13 was a potent inhibitor of the human U87MG glioblastoma cells at nanomolar concentrations, being nearly one order of magnitude superior to previously reported arylthioindoles. The present results highlight 13 as a robust scaffold for the design of new anticancer agents.
Lingua originale | English |
---|---|
pagine (da-a) | 283-297 |
Numero di pagine | 15 |
Rivista | European Journal of Medicinal Chemistry |
Volume | 152 |
DOI | |
Stato di pubblicazione | Pubblicato - 2018 |
Keywords
- Antineoplastic Agents
- Cancer cell
- Cell Proliferation
- Cell Survival
- Dose-Response Relationship, Drug
- Drug Screening Assays, Antitumor
- Humans
- Indole
- Indoles
- Inhibitor
- Microtubule
- Molecular Structure
- Polymerization
- Structure-Activity Relationship
- Tubulin
- Tubulin Modulators
- Tumor Cells, Cultured